Ben Hunt is a product analyst at Sleuth Insights, where he covers metabolic disease, I&I and oncology. He writes Sleuth's quarterly intelligence reports on GLP-1 and metabolic drugs, T-cell engagers, in vivo cell therapy and protein degraders, and he delivers Sleuth Concierge engagements for clients. Before Sleuth he was at ClearView Healthcare Partners, a life sciences strategy consultancy, where he specialized in pricing, market access and pharma M&A. He holds an B.S. in biochemistry from the University of Chicago.
